Latest news and press releases about Black Diamond Therapeutics, Inc. (BDTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor.
Price
| Price | $1.94 |
| Market Cap | $111M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.15 |
| EV / EBITDA | -2.92 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -38.80% |
| Return on Invested Capital | -45.91% |
| Return on Assets | -34.04% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AARD · ABEO · AVTX · CRBU · ENTA · FENC · FHTX
Explore sector: Healthcare · Biotechnology
More sections of BDTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks